Plasma lipoproteins with hydrated densities less than 1.063 g/ml, very low density, intermediate density, and low density lipoproteins, suppress mitogen-activated inductive biochemical events in lymphocytes. The ability of these lipoproteins to inhibit phytohemagglutinin (PHA)-enhanced incorporation of 32P into lymphocyte phospholipids correlates directly with the amount of associated apoprotei...

Lipoprotein(a) consists of a low-density lipoprotein containing apolipoprotein (apo) B-100 and of the genetically polymorphic apo(a). It is not known where and how lipoprotein(a) is assembled and whether there exists a precursor for lipoprotein(a). We have determined the phenotype, concentration, and distribution of apo(a) in plasma from patients with lipoprotein lipase (LPL) deficiency (type I...

The effects of experimental nephrosis in rats, produced by puromycin aminonucleoside, include an elevation of plasma levels of all lipoprotein density classes and the appearance of high density lipoprotein (HDL) rich in apoprotein (apo) A-I and deficient in apo A-IV and apo E. The hyperlipoproteinemia is associated with an increase in hepatic synthesis of lipoproteins. The possible role of decr...

Triglyceride-rich lipoprotein apoprotein catabolism was studied in rats from 5 to 60 min after intravenous injection of 125I-labeled lipoproteins. The plasma and liver labeled apoprotein content was analyzed by gel filtration column chromatography using an elution buffer containing 1% sodium dodecyl sulfate. The method resolved two B apoproteins of lower (apo B1) and higher (apo Bh) molecular w...

T he importance of lipid, lipoprotein, and apolipoprotein risk factors in the prediction, prevention, and regression of atherosclerosis is now well established. The role of elevated low density lipoprotein cholestexol (LDL C) in the development of coronary heart disease (CHD) is supported by evidence from numerous epidemiologic studies, clinical trials, and genetic studies.1-3 High density lipo...

Apolipoprotein (apo) E polymorphism was among the first-reported genetic polymorphisms that explained part of the normal variation in plasma cholesterol concentrations in humans. The aim of this study was to assess the influence of allelic variation at the apo E gene locus on the plasma lipoprotein profile in hyperlipidemia. The lipoprotein levels of hyperlipidemic subjects of the major apo E p...

Probucol is a hypolipidemic agent that causes a marked decrease in high density lipoprotein (HDL) cholesterol. To investigate the mechanism of this effect, two studies were performed in hypercholesterolemic patients who had been stabilized previously on diet and were not receiving other lipid-lowering medication. Plasma cholesteryl ester transfer protein (CETP) concentrations were measured in f...

T he importance of lipid, lipoprotein, and apolipoprotein risk factors in the prediction, prevention, and regression of atherosclerosis is now well established. The role of elevated low density lipoprotein cholestexol (LDL C) in the development of coronary heart disease (CHD) is supported by evidence from numerous epidemiologic studies, clinical trials, and genetic studies.1-3 High density lipo...

The genes for apolipoprotein (apo) C-II, a cofactor for activation of lipoprotein lipase, and apo E, a ligand for receptor-mediated uptake of triglyceride-rich lipoproteins, are physically linked on chromosome 19q13.1. In a large Caribbean Caucasian family, several individuals had clinical features of the complete absence of lipoprotein lipase activity and were homozygous for a DNA frameshift m...

We have reported previously that canine livers possess two distinct lipoprotein receptors, an apoprotein (apo)-B,E receptor capable of binding the apo-B-containing low density lipoproteins (LDL) and the apo-E-containing cholesterol-induced high density lipoproteins (HDLc), and an apo-E receptor capable of binding apo-E HDLc but not LDL. Both the apo-B,E and apo-E receptors were found on the liv...